Neuberger Berman Group LLC Avrobio, Inc. Transaction History

Neuberger Berman Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$10.54 - $19.3 $1.15 Million - $2.1 Million	-109,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$12.99 - $19.41 $220,830 - $329,970	17,000 Added 18.48%	109,000 $1.42 Million
Q2 2020 Aug 13, 2020	BUY	$12.19 - $22.96 $414,460 - $780,640	34,000 Added 58.62%	92,000 $1.61 Million
Q1 2020 May 14, 2020	BUY	$10.08 - $27.21 $282,240 - $761,880	28,000 Added 93.33%	58,000 $902,000
Q4 2019 Feb 12, 2020	BUY	$13.05 - $21.88 $391,500 - $656,400	30,000 New	30,000 $604,000

28.1M

100

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.